Clinical trials: Metastatic Cutaneous Squamous Cell Carcinoma
Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
This phase I trial studies the best dose and side effects of abexinostat and how well it works with given together with pembrolizumab in treating participants with microsatellite instability (MSI) solid tumors that have spread to…
- Conditions
- Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm
- Trial name
- NCT03590054
- Testing
- Abexinostat, Pembrolizumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Rahul Aggarwal
Squamous Cell Carcinoma of the Skin
Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response…
- Trial name
- NCT04204837
- Testing
- Nivolumab, Nivolumab plus Relatlimab
- Where
- 7 sites in Austria
- Volunteers
- 61 people
- Sponsor
- Salzburger Landeskliniken
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT07602842
- Testing
- IDP-001
- Where
- 6 sites in United States
- Volunteers
- 132 people
- Sponsor
- InduPro, Inc.
Cancer
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00900302
- Testing
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- OHSU Knight Cancer Institute
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
This phase I trial studies the best dose of sonidegib when given together with pembrolizumab and to see how well they work in treating patients with solid tumor that has spread to other places in the body (advanced).
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT04007744
- Testing
- Pembrolizumab, Sonidegib
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement…
- Conditions
- Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT06589804
- Testing
- Biospecimen Collection, Cetuximab, Computed Tomography
- Where
- 202 sites in United States
- Volunteers
- 158 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
This phase I trial evaluates the safety and effectiveness of in situ immunomodulation with CDX-301, radiotherapy, CDX-1140 and Poly-ICLC (Cohort A) and these with intravenous (IV) pembrolizumab and subcutaneous (SC) tocilizumab…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma
- Trial name
- NCT04616248
- Testing
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Southern California
Metastatic Melanoma, Squamous Cell Skin Carcinoma
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
This is a Phase 1b open-label dose escalation trial of Ad/MG1-MAGEA3 and Pembrolizumab in patients with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed prior standard of care treatments.
- Trial name
- Pelican (NCT03773744)
- Testing
- Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab
- Sponsor
- Turnstone Biologics, Corp.
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
This is a Phase Ib/II multi-center, open-label study of HMBD-001 in combination with cetuximab with or without docetaxel in participants with advanced Squamous Cell Cancers
- Conditions
- Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT05910827
- Testing
- HMBD-001, Docetaxel, Cetuximab
- Where
- 20 sites in Australia, Moldova and 3 more
- Volunteers
- 398 people
- Sponsor
- Hummingbird Bioscience
Squamous Cell Carcinoma of the Skin
Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin
This study intends to conduct a single-arm, prospective and open clinical study, using carrellizumab combined with albumin-binding paclitaxel regimen for first-line treatment of squamous cell carcinoma of the skin, including 24…
- Trial name
- NCT05886140
- Testing
- Carrilizumab with albumin-binding paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Henan Cancer Hospital
Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx).
- Conditions
- Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer
- Trial name
- POTENTIATE (NCT05827614)
- Testing
- BBI-355, Erlotinib, Futibatinib
- Where
- 16 sites in United States
- Volunteers
- 85 people
- Sponsor
- Boundless Bio, Inc.
Melanoma, Skin Cancer
The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors
In this study, we compared a negative pressure wound therapy, versus a conventional dressing in order to evaluate the most efficient wound therapy closure after axillary and inguinal lymph nodes dissections in the management of…
- Conditions
- Melanoma, Skin Cancer, Epidermoid Carcinoma, Neuroendocrine Carcinoma
- Trial name
- NCT04583605
- Testing
- PREVENA
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Central Hospital, Nancy, France
Advanced Malignancies, Metastatic Cancer
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
- Trial name
- NCT03277352
- Testing
- INCAGN01876, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Incyte Biosciences International Sàrl
Advanced Solid Tumor, Cutaneous Tumor
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed…
- Conditions
- Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor
- Trial name
- ANCHOR (NCT06171750)
- Testing
- tolododekin alfa, Cemiplimab
- Where
- 5 sites in United States, Canada
- Volunteers
- 97 people
- Sponsor
- Ankyra Therapeutics, Inc
Cutaneous Squamous Cell Carcinoma
The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
Following basal cell carcinoma, Cutaneous Squamous Cell Carcinoma (CSCC) is the most common skin cancer and its incidence remains on a steady rise.
- Trial name
- NCT05238363
- Testing
- HLX07
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Henlius Biotech
HNSCC, Lip SCC
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
This is a prospective, multi-center, open-label, non-randomized, multi-arm phase II trial to evaluate the efficacy of combination therapy with pembrolizumab and cetuximab for patients with recurrent/metastatic HNSCC.
- Conditions
- HNSCC, Lip SCC, Oral Cavity Cancer, Oropharynx Cancer
- Trial name
- NCT03082534
- Testing
- Pembrolizumab, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of California, San Diego
Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
This is a single-arm, non-randomized pilot study to evaluate the efficacy and tolerability of combination quad-shot palliative radiotherapy with immunotherapy for advanced/recurrent/metastatic head and neck cancer.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT04454489
- Testing
- Pembrolizumab (immunotherapy), Quad-shot palliative radiotherapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
This phase I/II trial studies the best dose and side effects of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and nivolumab and to see how well they work in treating patients with non-small cell lung cancer or…
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, PD-L1 Positive
- Trial name
- NCT02955290
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 51 people
- Sponsor
- Roswell Park Cancer Institute
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.